Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complete Remission Study
NCT07268313Phase 4Recruiting
- Sponsor
- Rigshospitalet
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab, mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Rigshospitalet. Started Apr 2025; status: recruiting.
02
Drugs
dupilumabmepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT07268313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268313.